JB Chemicals zooms over 2 per cent on launching Renova division

JB Chemicals & Pharmaceuticals Ltd (JBCPL), a domestic pharmaceutical company, announced this afternoon that it has forayed into the nephrology segment by launching a new dedicated division called 'Renova'. 

The new division will endeavour in serving patients, who are undergoing the treatment for chronic kidney disease (CKD).  

The newly-launched division will focus exclusively on comprehensive renal care, which ranges from the management of hypertension in chronic kidney disease to end-stage renal disease. Earlier, the company, which had become successful in the treatment of hypertension with its brands such as Cilacar & Nicardia, is now focussing on patients with CKD.  

Nikhil Chopra, CEO & Whole Time Director at JBCPL, says, “Being one of the leaders in the hypertension segment, we realised that chronic kidney disease is a major issue in the country and its numbers are rising significantly. There are growing cases of hypertension associated with CKD and we believe this initiative will enable us to serve the growing unmet needs of CKD patients. JBCPL remains committed to serving the needs of the patients and the launch of the dedicated nephrology division is a testament to that fact. Besides the division launch, we will continue to create awareness about CKD and enable patients to reach out to physicians as early as possible.”   

At the time of market closing on Thursday, the company’s stock was trading at Rs 1,453.40, up by 2.62 per cent on BSE.